目的 探讨喹硫平联合美金刚治疗阿尔茨海默病(Alzheimer's disease,AD)伴发痴呆精神行为症状(behavioral and psychological symptoms of dementia,BPSD)的临床效果及对照料者精神负担的影响。方法 选取2020-01至2021-01在解放军总医院第六医学中心住院诊断AD合并BPSD的患者60例及其照料者60名。患者均为男性,随机分为试验组和对照组,每组30例。对照组给予美金刚治疗,试验组使用美金刚联合喹硫平治疗,治疗4周。治疗前和治疗4周后评测MoCA、BEHAVE-AD及其照料者SCL-90评分。结果 治疗前两组患者的MoCA、BEHAVE-AD评分及照料者SCL-90评分比较,差异无统计学意义(P＞0.05)。试验组及对照组治疗后的患者MoCA评分均较治疗前改善,差异有统计学意义(P＜0.05)。试验组治疗后患者BEHAVE-AD评分、照料者SCL-90评分均较治疗前改善,差异有统计学意义(P＜0.05),对照组治疗后的患者BEHAVE-AD评分、照料者SCL-90评分均较治疗前无改善,差异无统计学意义(P＞0.05)。结论 美金刚联合喹硫平较单用美金刚治疗效果好,有助于减轻照料者的精神负担。
Abstract
Objective To investigate the clinical effect of quetiapine combined with memantine in the treatment of behavioral and psychological symptoms of dementia (BPSD)of Alzheimer's disease and its influence on the mental burden of the caregivers. Methods Sixty male patients diagnosed as AD combined with BPSD who were treated in The Sixth Medical Center of Chinese PLA General Hospital from January 2020 to January 2021 as well as 60 caregivers were randomly divided into experimental group (n=30) and control group (n=30). The control group were treated with Memantine, while the experimental group were treated with memantine combined with quetiapine for 4 weeks. Before treatment and at the end of 4 weeks' treatment, evaluation of MoCA, BEHAVE-AD and their caregivers' SCL-90 scores was made. Results Before treatment of both groups, there was no significant difference (P>0.05) in MoCA, BEHAVE - AD and caregivers' SCL-90 score. MoCA scores in both groups after treatment were improved, and the difference was statistically significant (P<0.05). After treatment, the BEHAVE-AD score and caregiver SCL-90 score in the experimental group were improved, and the difference was statistically significant (P<0.05), while those scores in the control group were not improved and there was no statistical difference (P>0.05). Conclusions Quetiapine combined with memantine has a better therapeutic effect and it can also help relieve the mental burden of the patient's caregivers.
关键词
阿尔茨海默病 /
痴呆 /
精神和行为症状 /
喹硫平 /
照料者负担
Key words
Alzheimer's disease /
dementia /
behavioral and psychological symptoms /
quetiapine /
caregiver burden
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Soria L J A, González H M, Léger G C. Alzheimer's disease[J]. Handb Clin Neurol,2019,167(5):231-255.
[2] Eratne D, Loi S M, Farrand S, et al. Alzheimer's disease: clinical update on epidemiology, pathophysiology and diagnosis[J]. Australas Psychiatry,2018,26(4):347-357.
[3] Ohno Y, Kunisawa N, Shimizu S. Antipsychotic treatment of behavioral and psychological symptoms of dementia (BPSD): management of extrapyramidal side effects[J].Front Pharmacol,2019,10(5):1045.
[4] Yunusa I, Alsumali A, Garba A E, et al. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis [J].JAMA Netw Open,2019,2(3):e190828.
[5] Bessey L J, Walaszek A. Management of behavioral and psychological symptoms of dementia [J]. Curr Psychiatry Rep,2019, 21(8):66.
[6] Liu Z, Heffernan C, Tan J. Caregiver burden: a concept analysis[J]. Int J Nurs Sci, 2020,7(4):438-445.
[7] Bergvall N,Brinck P,Eek D, et al. Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease [J].Int Psychogeriatr,2011,23(1):73-85.
[8] Chakraborty S, Lennon J C, Malkaram S A ,et al. Serotonergic system, cognition, and BPSD in Alzheimer's disease[J]. Neurosci Lett,2019,704(6):36-44.
[9] Preuss U W, Wong J W, Koller G.Treatment of behavioral and psychological symptoms of dementia: a systematic review[J]. Psychiatr Pol,2016,50(4):679-715.
[10] Magierski R, Sobow T, Schwertner E, et al. Pharmacotherapy of behavioral and psychological symptoms of dementia: state of the art and future progress[J].Front Pharmacol,2020,11(2):1168.
[11] Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis[J]. Int J Geriatr Psychiatry,2008,23(4):537-545.
[12] Fox C, Crugel M, Maidment I, et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial[J]. PLoS One, 2012,7(3):e35185.
[13] Kales H C,Gitlin L N,Lyketsos C G.Assessment and management of behavioral and psychological symptoms of dementia [J].BMJ,2015,350(3):h369.
[14] Schneider L S,Dagerman K,Insel P S.Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials[J]. Am J Geriatr Psychiatry,2006,14(3):191-210.
[15] Tulek Z,Bayka D,Erturk S, et al. Caregiver burden, quality of life and related factors in family caregivers of dementia patients in Turkey [J]. Issues Ment Health Nurs,2020,41(8):741-749.
[16] Liu S, Li C H, Shi Z H,et al.Caregiver burden and prevalence of depression, anxiety and sleep disturbances in Alzheimer's disease caregivers in China[J].J Clin Nurs, 2017,26(9):1291-1300.
[17] Kieboom R V D,Snaphaan L,Mark R,et al. The trajectory of caregiver burden and risk factors in dementia progression: a systematic review[J]. J Alzheimers Dis,2020,77(3):1107-1115.
[18] Lloyd J, Muers J, Patterson T G,et al. Self-compassion, coping strategies, and caregiver burden in caregivers of people with dementia[J].Clin Gerontol, 2019,2(1):47-59.
[19] Yu H M, Wang X C, He R L,et al.Measuring the caregiver burden of caring for community-residing people with Alzheimer's disease[J]. PLoS One, 2015,10(7):e0132168.
[20] Tsai C F, Hwang W S, Lee J J, et al. Predictors of caregiver burden in aged caregivers of demented older patients[J] .BMC Geriatr, 2021,21(1):59.
[21] Alzheimer's Association.2016 Alzheimer's disease facts and figures[J].Alzheimers Dement,2016,12(4):459-509.
PDF(981 KB)
